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Atrial  ﬁbrillation  (AF)  is one  of  the  common  cardiac  arrhythmias  and  is  responsible  for increased  mor-
tality  and  various  morbidities.  The  prevalence,  mortality,  morbidity,  and  treatment  strategy  for  AF  might
differ between  Western  countries  and  Asian  countries  including  Japan.  AF  prevalence  in elderly  sub-
jects  (≥80  years  old)  is relatively  low  in  Japan,  Korea,  and  Taiwan  as compared  with  Western  countries.
In  contrast,  the  prevalence  in mainland  China  is  intermediate  between  Japan  and  Western  countries.
CHADS2 score and  its new  version,  CHA2DS2-VASc  score,  are  useful  to  predict  subsequent  thromboem-pidemiology
hromboembolism
nticoagulation
bolic  events  in Japanese  AF  patients.  Guidelines  in  Western  countries  recommend  target  anticoagulation
levels  for  prevention  of thromboembolic  and  major  hemorrhagic  events  at prothrombin  time  interna-
tional  normalized  ratio  (PT-INR)  of 2–3.  However,  relatively  lower  PT-INR  levels  could  be  suitable  for
prevention  of  these  events  among  patients  with  nonvalvular  AF  in  Japan  and  China.  New  oral  anticoagu-
lants  have  been  launched  in Japan  as  an  alternative  to warfarin.  The  management  strategy  for  AF  patients
needs  to be  modiﬁed  based  on  the  data  obtained  from  Japanese  patients.©  2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
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ntroduction
Atrial ﬁbrillation (AF) is one of the common cardiac arrhyth-
ias encountered in clinical practice. AF is responsible for increased
ortality and various morbidities including symptoms, cardiac
ysfunction and thromboembolic events [1–4]. Epidemiological
tudies showed the prevalence of AF increased with the aging of
he population [5–7]. Several predisposing factors for AF other
For instance, the prevalence of hypertension seems higher in Japan
than in the USA, but lower in Japan than in England and Germany
[12–14]. The incidence of myocardial infarction is lower and the
prognosis after myocardial infarction is better in Japan than in
Western countries [15,16].
The present review aimed to clarify the difference in epidemi-
ology of AF, risk factors for thromboembolism, and antithrombotic
treatment between Western countries and Asian countries includ-han aging are known. Among them are hypertension, coronary
rtery disease, congestive heart failure, and others [8–11]. The
revalence, mortality, and morbidity of these diseases might differ
etween Western countries and Asian countries including Japan.
∗ Tel.: +81 76 434 7297; fax: +81 76 434 5026.
E-mail address: hiroshi@med.u-toyama.ac.jp
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.08.012ing Japan.
Epidemiology of AFEpidemiological studies from Western countries showed the
increase in the prevalence of AF became striking after the age of
60 years, affecting approximately 8–9% of people aged 80 years or
more [5–7]. In the Framingham Study [17], the prevalence of AF was
vier Ltd. All rights reserved.
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hig. 1. Prevalence of atrial ﬁbrillation in elderly subjects ≥80 years old in Asian and
estern countries. Data for Taiwan were obtained from subjects aged ≥75 years.
.1% for people aged 40–49 years, and increased to 8.8% for people
ged ≥80 years. A general practice research database in England
nd Wales showed the prevalence of AF was more than 10% for
eople aged ≥85 years [7].  Other investigators [6] also reported
imilar ﬁgures for AF prevalence.
In Japan, epidemiological studies on AF were limited in number.
akayama et al. indicated in 1997 that the prevalence of AF was
.35% among 2305 residents of a community whose age was 40
ears or more [18]. The prevalence of AF in the study of 23,713
ubjects by Ohsawa et al. was 3.8% for men  and 2.2% for women aged
70 years [19]. An analysis of the prevalence of AF based on periodic
ealth examination in 2003 was performed [20]. Data from 630,138
ubjects aged ≥40 years (men, 47%) were collected from northern
o southern Japan. The AF prevalence increased as both men  and
omen aged, and it was 4.4% for men  but only 2.2% for women  aged
80 years. As a whole, the AF prevalence of men  was 3 times that
f women (1.35% vs. 0.43%). A similar result was reported by Iguchi
ho analyzed the data of health examination in Kurashiki city in
006 [21]. AF prevalence was 3.5% for men  and 2.5% for women
ged ≥80 years [21].
Epidemiological studies on the AF prevalence in Asian countries
ere also limited in number [22]. In 1996, Lok and Lau reported
hat the prevalence of AF was only 1.3% in ambulatory elderly
eople aged 60 to 94 years in Hong Kong [23]. Recently, several
pidemiological studies have been reported. Chien et al. performed
 prospective, community based cohort study in Taiwan [24]. As
xpected the AF prevalence increased as the people aged, and it
as 3.67% of people aged ≥75 years. Jeong reported a similar preva-
ence of AF among subjects aged ≥80 years in Korea, i.e. 4.5% for
en  and 3.5% for women [25]. However, the AF prevalence among
eople of mainland China was intermediate between that of West-
rn countries and that of Japan and other Asian countries. Zhou
t al. determined AF prevalence among 29,079 subjects from 14
rovinces of mainland China, and it was 7.5% for men  and 7.4%
or women aged ≥80 years [26]. Yap et al. reported AF prevalence
mong Chinese people living in Singapore as 11.1% for men  and only
.5% for women aged ≥80 years, based on a population based study
27]. These Chinese studies were limited because of the relatively
mall number of subjects studied. The total number of subjects aged
80 years was only 294 for the study of Zhou and Hu [26] and 120
or the study of Yap [27]. The Japanese data were based on more
han 10,000 subjects for both men  and women aged ≥80 years [20].
n Fig. 1, AF prevalence of subjects aged ≥80 years is compared
mong Asian and Western countries.
Based on the data of the population-based survey, an earlier
tudy estimated that there could be 2.23 million people in the USA
aving AF, an overall prevalence of 0.89% in 1995 [5]. It would belogy 61 (2013) 1–7
0.65 million people in England and Wales, an overall prevalence
of 1.25% in 2001 [7]. Our Japanese study estimated the number of
people having AF as 0.72 million in Japan, an overall prevalence of
0.56% in 2003 [20]. This Japanese prevalence was almost two-thirds
of the USA prevalence. Future population numbers with AF could
be projected using these epidemiological data. Based on the ATRIA
study, the number of people having AF was expected to increase
to 5 million in the USA in 2050 [6]. Because there were trends in
increasing incidence of AF, Miyasaka et al. estimated the number
to be 12–16 million in the USA by the year 2050 [28]. In contrast,
Japanese studies estimated the number to be much lower as com-
pared with that in USA. For example, Ohsawa et al. estimated it to
be 1.08 million in 2030 [19]. Our data estimated it to be 1.05 mil-
lion in 2030 and 1.03 million in 2050, if the AF prevalence were to
keep constant [20]. This modest increase in the future number of
Japanese people with AF could be attributed to a decrease in the
number of people aged 50–69 years, although number of people
aged ≥80 years would be doubled in 2050 [20]. Our future projec-
tion of the number of people having AF would be underestimated,
because the prevalence of AF could be increased in the future [28],
and subjects having paroxysmal AF could not be diagnosed based
on a single electrocardiographic recording.
Underlying diseases of AF
Hypertension was  the most frequent co-morbidity of patients
with AF in the Framingham [8], ATRIA [6],  and AFFIRM studies [29];
it accounted for almost 50% of the subjects. In the earlier stud-
ies of Japanese AF patients reported in 1998–2000, hypertension
accounted for 20–30% of the subjects, and so-called lone AF for
20–30% [30,31]. Co-morbidities could change over time, and the
prevalence of the so-called lone AF was  decreasing. The Euro Heart
Survey showed in 2005 that hypertension accounted for approxi-
mately 60% and coronary artery disease for 30% [32]. The J-RHYTHM
registry [33], an observational study on the status of antithrom-
botic therapy and optimal intensity of anticoagulation among AF
subjects, showed in 2011 that hypertension accounted for 60%, a
ﬁnding consistent with the Euro Heart Survey [32]. Hypertension
was also the most frequent co-morbidity of AF in Chinese people,
and ranged from 54% to 73% in frequency [26,27].  However, the
prevalence of coronary artery disease was  lower in Japan and other
Asian countries. It was  approximately 10% in J-RHYTHM registry
[33], only one third of the prevalence in the Euro Heart Survey [32];
this was  also true for Chinese studies [26,27].
The difference in co-morbidities between Japan and Western
countries could contribute to the difference in the incidence of
cardiogenic embolism in AF patients (see below).
Risk factors for cardiogenic embolism in AF
Thromboembolic events were a complication in 5 times more
with subjects with AF as compared with subjects in sinus rhythm
[18]. Several clinical characteristics emerged as independent risk
factors for thromboembolism in patients with nonvalvular AF
[35–37]. Although risk factors varied to some extent among studies,
many physicians preferred CHADS2 score to other schemes for risk
stratiﬁcation of thromboembolism in patients with nonvalvular
AF [35]. This score utilizes congestive heart failure, hypertension,
age (≥75 years), diabetes, and prior stroke or transient ischemic
attack. Currently, a modiﬁcation of CHADS2 score, i.e. CHA2DS2-
VASc score, is proposed as an alternative to the classic CHADS2
score [37]. Vascular diseases, age between 65 and 74 years, and
sex category (female) were incorporated in the classic CHADS2
score to deﬁne the truly low-risk patients for thromboembolism.
These schemes [35,37] were proposed based on the clinical data of
H. Inoue / Journal of Cardio
Table  1
Independent risk factors for thromboembolic events (Cox proportional hazard
model).
Clinical variables Hazard ratio p-Value
Heart failure (NYHA class ≥II) 1.809 0.012
Male sex 1.779 0.018
Hypertension 1.715 0.021
Diabetes mellitus 1.704 0.091
Age  ≥65 years 1.418 0.158
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c = 801, without receiving any antithrombotic drugs. Mean age, 58 years [38]. NYHA,
ew York Heart Association.
estern countries, and therefore, should be validated for use in
apanese patients with nonvalvular AF.
Based on the data from 801 Japanese subjects with AF but not
eceiving any antithrombotic medication, 3 independent risk fac-
ors were identiﬁed (Table 1) [38]. They were symptomatic heart
ailure, male sex, and hypertension. Diabetes and age (≥65 years)
howed a marginal signiﬁcance. Female gender did not emerge
s a risk factor. In Fig. 2, thromboembolic event rates are com-
ared among 3 risk levels of CHADS2 score; CHADS2 score of 0
as deﬁned as low risk; 1 to 2, moderate risk; and 3 or more, high
isk [39]. Japanese patients with nonvalvular AF but not receiv-
ng anticoagulants showed similar event rates to those in Western
ountries, when the risk level was adjusted with CHADS2 score.
his ﬁnding supports that CHADS2 score can be a useful risk strati-
cation scheme for Japanese people with nonvalvular AF. Recently,
omatsu et al. [40] indicated CHA2DS2-VASc score was  also useful
or risk stratiﬁcation among patients with nonvalvular, paroxysmal
F in Japan.
Transesophageal echocardiographic ﬁndings are known as
eing useful for risk stratiﬁcation of subsequent thromboembolic
vents in patients with AF. Among them are spontaneous echo con-
rast, ﬂow velocity in the left atrial appendage, and thrombi [41].
s shown in Fig. 3, along with an increase in the risk level with
HADS2 score, the degree of spontaneous echo contrast increased,
nd the ﬂow velocity in the left atrial appendage decreased [42].
his ﬁnding indicates that blood ﬂow is congested, thereby leading
o prothrombotic state in the left atrium of AF patients at higher
isk for thromboembolism.
Other useful factors for risk stratiﬁcation of thromboembolic
vents in AF patients are hemostatic markers. Fibrinolysis and
oagulation indices were elevated in patients with AF, and anti-
oagulation therapy or restoration of sinus rhythm would decrease
hese indices toward the normal ranges [43–47].  Platelet function
ig. 2. Rates of thromboembolic events and risk levels according to CHADS2 score
39].  Thromboembolic event rates of patients in Japan are similar to those in Western
ountries, when the risk level is stratiﬁed with CHADS2 score.logy 61 (2013) 1–7 3
was also elevated in AF patients [44,47]. These indices increased
in AF patients when the risk level was increased [48]. Anticoagu-
lation with warfarin could lower the elevated levels of ﬁbrinolysis
and coagulation indices, but did not affect platelet function [48]. A
prospective observational study determined the efﬁcacy of hemo-
static markers to predict subsequent thromboembolic events in
509 patients with nonvalvular AF [49]. d-Dimer was effective in
predicting thromboembolic events, but prothrombin fragments
1,2, platelet factor 4, and beta-thromboglobulin were not (Fig. 4).
Patients with nonvalvular AF who had elevated d-dimer level but
did not have clinical risk factors were at risk for subsequent throm-
boembolic events as compared with those without clinical risk
factors and elevated d-dimer levels. Usefulness of d-dimer level
for predicting subsequent cardiovascular events was also reported
by other investigators [50].
As with other cardiovascular diseases, prevalence of AF dif-
fers between men  and women  in Western countries [5–7] and
also in Japan [20,21]. Several studies have reported that there are
gender-related differences in clinical characteristics of AF patients
[51–53]. A prospective, cohort study reported from Europe indi-
cated that effects of AF on the risk of stroke were greater in women
than in men  after adjustment for age and co-morbidity [53]. Other
studies also showed that AF was associated with increased car-
diovascular events including mortality and stroke, especially in
women [52,54,55].  Some risk stratiﬁcation schemes [56,57] consid-
ered women to be at high risk of ischemic stroke, but other schemes
[35,36] did not. Gender-related differences in clinical characteris-
tics of Japanese patients with AF are determined with the registry
data of a large nation-wide multicenter, cooperative study, J-TRACE
[58]. Women  were older, and had congestive heart failure and
hypertension more frequently as compared with men. Prevalence
of subjects aged 75 years or older was  higher in women than in men.
Accordingly, CHADS2 score was  slightly but signiﬁcantly higher in
women than in men  (2.05 ± 1.29 vs. 1.88 ± 1.33, p < 0.001). This was
also true for the ATRIA study [52]. In the Euro Heart Survey [53],
the score could be higher in women  than in men, because mean
age and prevalence of hypertension, diabetes mellitus, and prior
ischemic stroke were signiﬁcantly higher in women than in men.
Some risk stratiﬁcation schemes [56,57] consider women to be
at high risk of ischemic stroke, and a new scheme of CHA2DS2-VASc
also incorporated women  as a risk factor for thromboembolism
[37]. As mentioned above, female sex did not emerge as an inde-
pendent risk factor for thromboembolism in Japanese studies [38].
Therefore, caution should be taken in employing CHA2DS2-VASc
score, in particular female sex, for the risk stratiﬁcation of Japanese
AF patients.
Antithrombotic therapy in AF
Several prospective, randomized trials reported that anticoag-
ulation with warfarin was  effective in preventing thromboembolic
events in patients with AF, but aspirin was inferior to warfarin
for prevention of thromboembolic events. A meta-analysis of 5
prospective studies indicated effectiveness of warfarin in 1994 [59].
In those days, frequency of warfarin use in Japanese patients with
AF was  quite low; only 14–19% in 1991–1995 (Table 2) [30,31].
However, warfarin use increased gradually thereafter, and reached
50% around the year 2000 [46]. Recently, warfarin is given to
approximately 80% of AF patients who  are treated by cardiologists
or neurologists [33,58]. However, anticoagulation was given to only
22% of AF patients referred for treatment of acute ischemic stroke
[60]. Japanese guidelines [61] recommend no antithrombotic treat-
ment for AF patients with CHADS2 score of 0; however, in a recent
observational study, warfarin was given to 77% of patients with
CHADS2 score 0 [62]. More than 90% of patients with CHADS2 score
4 H. Inoue / Journal of Cardiology 61 (2013) 1–7
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nig. 3. Transesophageal echocardiographic ﬁndings and risk levels according to CH
nd  blood ﬂow in the left atrial appendage (LAA) decreased (right) as the risk level 
f 3 or more received warfarin (Fig. 5). Gender-related difference
n warfarin use was not observed in recent observational studies in
apan [58,62].
In Western countries, international normalized ratios of pro-
hrombin time (PT-INR) between 2.0 and 3.0 were recommended
s the target anticoagulation levels with warfarin for prevention
f thromboembolic events in patients with AF [34]. Levels of PT-
NR less than 2.0 were not effective as antithrombotic therapy
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Event free survival
ig. 4. Thromboembolic events and hemostatic markers [49]. Kaplan–Meier event-free sur
o  plasma levels of each marker. Solid lines show patients with the level of the hemostati
he  level of the hemostatic marker exceeding the upper limit of the normal range. Only 
onvalvular atrial ﬁbrillation. PF4, platelet factor 4; F1,2, prothrombin fragments 1,2; TGscore (modiﬁed from [42]). Degree of spontaneous echo contrast increased (left)
mboembolism (CHADS2 score) increased.
for patients with AF. However, Yasaka et al. [63] indicated PT-
INR of 1.6–2.6 was effective for prevention of thromboembolic
events and major hemorrhagic complications based on prospec-
tive, secondary prevention studies. Mean PT-INR was  2.81 when
the major hemorrhagic events occurred, and the most patients
with major hemorrhagic events were aged ≥70 years. Therefore,
the current Japanese guidelines for management of AF recommend
PT-INR between 1.6 and 2.6 for patients aged ≥70 years who  have
0         200       400       600       800 10000
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vival curves are shown. In each panel, patients were divided into 2 groups according
c marker below the upper limit of the normal range. Dotted lines show those with
d-dimer levels could predict subsequent thromboembolic events in patients with
, beta-thromboglobulin.
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Table  2
Trends in warfarin use among patients with atrial ﬁbrillation in Japan.
Study Year of study Type of AF No. of patients (mean age, years) Warfarin use (%)
Arrhythmia Research Group [30] 1991–1993 NVAF, VAF 1970 (58.5) 18.6
Hokkaido AF Study Group [31] 1995 NVAF, VAF 2667 (67) 13.6
Inoue et al. [46] 1999 NVAF 509 (66.6) 51.7
J-TRACE [58] 2005–2007 NVAF, VAF 2892 (70.3) 73.0
F, VAF 7937 (69.7) 87.3
A lation.
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Fig. 6. Distribution of prothrombin time international normalized ratio (PT-INR)
levels in patients with nonvalvular atrial ﬁbrillation (adapted from J-RHYTHM reg-
istry [33]). Patients were divided into 2 groups according to age. Distribution of INR
the proportion of patients with nonvalvular AF meeting the target
INR level of the Japanese guidelines at each CHADS2 score [62]. The
proportion of patients meeting the target INR level increased as theJ-RHYTHM registry [33] 2009 NVA
F, atrial ﬁbrillation; NVAF, nonvalvular atrial ﬁbrillation; VAF, valvular atrial ﬁbril
onvalvular AF but do not have prior ischemic stroke or transient
schemic attack [61]. Recently, a retrospective cohort study showed
T-INR of 1.5–2.5 was associated with a low incidence of throm-
oembolic and major hemorrhagic events in elderly patients (≥70
ears old) with nonvalvular AF and a CHADS2 score ≥2 [64].
Relatively lower PT-INR levels seemed effective for prevention
f thromboembolic events among Chinese patients with AF. Cheung
t al. [65] retrospectively determined the optimal PT-INR for stroke
revention in Chinese patients with AF. Those with a mechanical
eart valve were excluded. The overall rate of combined events
f thromboembolism and serious hemorrhage was  lowest in the
T-INR range of 1.5 and 1.9. They recommended a lower PT-INR
ange of 1.5–3.0 being safe and effective for stroke prevention. You
t al. [66] indicated that the incidence of either hemorrhagic or
hromboembolic events was lowest at PT-INR values between 1.8
nd 2.4 among patients newly started on warfarin for various car-
iovascular diseases. The main indication for warfarin was  atrial
brillation in 72% of 491 patients studied. However, PT-INR values
f 2.0–3.0 were effective in preventing thromboembolic events of
orean patients with AF and CHADS2 score of 1 [67].
The J-RHYTHM registry aimed to determine status of antithrom-
otic treatment and optimal PT-INR levels for prevention of
hromboembolism [33,62]. Determinants of warfarin use were
nvestigated in 6324 patients having nonvalvular AF and CHADS2
core ≥1 [62]. On multivariate analysis, determinants of warfarin
se were age (≥60 years), AF type (persistent and permanent),
nd co-morbidities (congestive heart failure, diabetes mellitus, and
rior stroke or transient ischemic attack). Antiplatelet drug use was
 negative determinant of warfarin use [62]. This suggests some
hysicians still use antiplatelet drugs, mostly aspirin, as an alter-
ative to warfarin for prevention of thromboembolism in patients
ith AF in Japan. Previous studies indicated the reasons for the non-
se of warfarin were requirement of dosage titration, monitoring of
nticoagulation levels, hemorrhage risk, patient refusal, and others
68,69].
ig. 5. Rates of warfarin use and CHADS2 score (adapted from J-RHYTHM reg-
stry [62]). Warfarin use in patients with nonvalvular atrial ﬁbrillation increases
s  CHADS2 score increases from 0 to 2 and then plateaus at CHADS2 score of 3–6.levels at baseline was similar between patients aged ≥70 years and those younger
than 70 years old. Those with valvular or nonvalvular atrial ﬁbrillation were included
for the analysis.
Among subjects enrolled in the J-RHYTHM registry, distribution
of INR levels was compared. The distribution was similar between
subjects younger than 70 years old and those aged 70 years or more
(Fig. 6) [33]. This suggests Japanese physicians adopt INR levels
between 1.6 and 2.6 as the target levels for prevention of throm-
boembolism in AF patients irrespective of patients’ age. Fig. 7 showsCHADS2 score increased. Only 41% of patients with CHADS2 score
Fig. 7. Proportion of patients with nonvalvular atrial ﬁbrillation meeting the target
prothrombin time international normalized ratio (INR) levels at each CHADS2 score
(adapted from J-RHYTHM registry [62]). Proportion of patients who met  the target
INR levels of Japanese guidelines increased as CHADS2 score increased. Only 50–60%
of  those with CHADS2 scores of 1–3 achieved the target INR level.
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Fig. 8. Determinants of achievement of the target INR vs. lower INR in patients
receiving warfarin (logistic regression analysis) (adapted from J-RHYTHM registry
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[62]).  Those with valvular or nonvalvular atrial ﬁbrillation who received warfarin
ere included for the analysis. AF, atrial ﬁbrillation; CI, cerebral infarction; TIA,
ransient ischemic attack.
f 0 who received warfarin actually achieved the target INR levels,
lthough warfarin is not recommended for these patients [61]. Only
5–62% of those with CHADS2 scores of 2–4 achieved the target INR
evels [62]. This indicates that quality of control of anticoagulation
evel with warfarin is not high currently in Japan. Fig. 8 shows the
esults of multivariate analysis for determinants of meeting of the
arget INR levels vs. lower INR levels [62]. This analysis disclosed
hat lower INR levels than the target levels are likely to be shown by
F patients younger than 60 years old, those with paroxysmal AF
r diabetes mellitus, and those receiving antiplatelet drugs. These
esults indicate adherence to the guidelines [61] regarding antico-
gulation therapy was currently limited in Japan.
Preliminary analysis of the data of J-RHYTHM registry showed
hat INR levels of 1.6–2.6 were effective in preventing thromboem-
olic events. INR levels exceeding 2.6 were associated with major
emorrhagic events more frequently as compared with INR lev-
ls lower than 1.6. Therefore, INR levels of 1.6–2.6 seemed suitable
or prevention of thromboembolic events in Japanese patients with
onvalvular AF as suggested by Yasaka et al. in 2001 [63]. For
atients with valvular AF, INR levels of 2.0–3.0 would be recom-
ended following the guidelines of Western countries [34].
onclusion
AF is different between Asian and Western countries in terms of
pidemiology, clinical proﬁle, optimal anticoagulation levels, and
thers. New anticoagulants, i.e. a direct thrombin inhibitor [70,71]
nd a direct factor Xa inhibitor [72,73] have been launched in Japan
s an alternative to warfarin. Japanese patients were enrolled in the
orldwide trials of these new drugs; lower dosage of rivaroxaban
as used for Japanese patients as compared with patients in West-
rn countries [73]. In contrast, the dosage of dabigatran is similar
etween Japan and Western countries [71]. Guidelines for manage-
ent of AF patients need to be revised based on the data obtained
rom Japanese AF patients.
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